BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18001257)

  • 1. Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines.
    Rodriguez AR; Fishman MN
    Expert Opin Pharmacother; 2007 Dec; 8(17):2979-90. PubMed ID: 18001257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
    Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
    J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant and neoadjuvant therapy in renal cell carcinoma.
    Choueiri M; Tannir N; Jonasch E
    Curr Clin Pharmacol; 2011 Aug; 6(3):144-50. PubMed ID: 21827393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis.
    Repmann R; Goldschmidt AJ; Richter A
    Anticancer Res; 2003; 23(2A):969-74. PubMed ID: 12820332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy in renal cell carcinoma: advancing paradigms.
    Posadas EM; Figlin RA
    Oncology (Williston Park); 2012 Mar; 26(3):290-301. PubMed ID: 22545314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
    Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives in drug development for metastatic renal cell cancer.
    Basu B; Eisen T
    Target Oncol; 2010 Jun; 5(2):139-56. PubMed ID: 20689997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in targeted therapy for renal cell carcinoma.
    Clark PE
    Curr Opin Urol; 2007 Sep; 17(5):331-6. PubMed ID: 17762626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy for advanced renal cell carcinoma.
    Meissner MA; McCormick BZ; Karam JA; Wood CG
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment in renal cell carcinoma.
    Dizman N; Adashek JJ; Hsu J; Bergerot PG; Bergerot CD; Pal SK
    Clin Adv Hematol Oncol; 2018 Aug; 16(8):555-563. PubMed ID: 30148828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
    Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
    J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory Therapies for Renal Cell Carcinoma.
    Liu M; Wu H; Shangguan D; Jiang Y; Li X; Liu S; Zhou B; Yin T; Gong Z
    Protein Pept Lett; 2018; 25(6):534-547. PubMed ID: 29848257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.